Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation

Table 2 Integrated selection criteria schemes for liver transplantation in hepatocellular carcinoma patients

Ref.	Model	No. of Patients	Parameters	Cut-off (points)	Criteria	Endpoint	Criteria-in outcome	Criteria-out outcome	Validation
Toso et al[26]	TTV/AFP	6478	TTV	≤ 115 cm³, > 115 cm³	TTV ≤ 115 cm³ AND AFP ≤ 400 ng/mL	Corrected posttransplant 3-yr OS	> 65%	< 50%	Grat et al: 104 patients with similar results
			AFP	≤ 400 ng/mL, > 400 ng/mL
Duvoux et al[20]	The AFP Model	Training cohort: 597 Validation cohort: 435	Longest Diameter	< 3 cm (0), 3-6 cm (1), > 6 cm (4)	Sum of individual points ≤ 2	posttransplant 5-yr RFS	7.7 % (Milan-in) 14.4% (Milan-out)	53.3 % (Milan-in) 47.6 % (Milan-out)	Notarpaolo et al[44]: 560 patients with similar results
			No. of nodules	1-3 (0), ≥ 4 (2)
			AFP	< 100 ng/mL (0), 100-1000 (2), > 1000 (3)
Lai et al[211]	-	422	mRECIST	Progression vs No progression	No progression AND AFP solpe ≤ 15	5-yr RFS 5-yr OS	RFS: 90% (Milan-in), 87% (Milan-out) OS: 88% (Milan-in), 83.5% (Milan-out)	RFS: 67.7% (Milan-in) 47% (Milan-out) OS 67.3% (Milan-in) 55.4% (Milan-out)	Not yet validated
			AFP slope	≤ 15 ng/mL per mo, > 15 ng/mL per mo

AFP: Alpha-fetoprotein.